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Abstract: OBJECTIVE Inherited or acquired mutations in the heme biosynthetic pathway leads to a
debilitating class of diseases collectively known as porphyrias, with symptoms that can include anemia,
cutaneous photosensitivity, and neurovisceral dysfunction. In a genetic screen for hematopoietic mutants,
we isolated a zebrafish mutant, montalcino (mno), which displays hypochromic anemia and porphyria.
The objective of this study was to identify the defective gene and characterize the phenotype of the
zebrafish mutant. MATERIALS AND METHODS Genetic linkage analysis was utilized to identify
the region harboring the mno mutation. Candidate gene analysis together with reverse transcriptase
polymerase chain reaction was utilized to identify the genetic mutation, which was confirmed via allele-
specific oligo hybridizations. Whole mount in situ hybridizations and o-dianisidine staining were used to
characterize the phenotype of the mno mutant. mRNA and morpholino microinjections were performed
to phenocopy and/or rescue the mutant phenotype. RESULTS Homozygous mno mutant embryos have
a defect in the protoporphyrinogen oxidase (ppox) gene, which encodes the enzyme that catalyzes the
oxidation of protoporphyrinogen. Homozygous mutant embryos are deficient in hemoglobin, and by 36
hours post-fertilization are visibly anemic and porphyric. The hypochromic anemia of mno embryos was
partially rescued by human ppox, providing evidence for the conservation of function between human and
zebrafish ppox. CONCLUSION In humans, mutations in ppox result in variegate porphyria. At present,
effective treatment for acute attacks requires the administration intravenous hemin and/or glucose. Thus,
mno represents a powerful model for investigation, and a tool for future screens aimed at identifying
chemical modifiers of variegate porphyria.
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Abstract
Objective—Inherited or acquired mutations in the heme biosynthetic pathway lead to a debilitating
class of diseases collectively known as porphyrias, with symptoms that can include anemia,
cutaneous photosensitivity, and neurovisceral dysfunction. In a genetic screen for hematopoietic
mutants, we isolated a zebrafish mutant, montalcino (mno), which displays hypochromic anemia and
porphyria. The objective of this study was to identify the defective gene and characterize the
phenotype of the zebrafish mutant.
Methods—Genetic linkage analysis was utilized to identify the region harboring the mno mutation.
Candidate gene analysis together with RT-PCR was utilized to identify the genetic mutation, which
was confirmed via allele specific oligo hybridizations. Whole mount in situ hybridizations and 0-
dianisidine staining were used to characterize the phenotype of the mno mutant. mRNA and
morpholino microinjections were performed to phenocopy and/or rescue the mutant phenotype.
Results—Homozygous mno mutant embryos have a defect in the protoporphyrinogen oxidase
(ppox) gene, which encodes the enzyme that catalyzes the oxidation of protoporphyrinogen.
Homozygous mutant embryos are deficient in hemoglobin, and by 36 hpf are visibly anemic and
porphyric. The hypochromic anemia of mno embryos was partially rescued by human ppox, providing
evidence for the conservation of function between human and zebrafish ppox.
Conclusion—In humans, mutations in ppox result in variegate porphyria. At present, effective
treatment for acute attacks requires the administration intravenous hemin and/or glucose. Thus,
mno represents a powerful model for investigation, and a tool for future screens aimed at identifying
chemical modifiers of variegate porphyria.
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Introduction
Porphyrias are a class of diseases resulting from mutations in seven of the eight enzymes in
the heme biosynthetic pathway, resulting in an abnormal accumulation of the pathway
intermediates, known as porphyrins (reviewed in [1],[2],[3]). The clinical symptoms of the
disease can present as an erythrocytic or hepatic syndrome with cutaneous manifestations,
depending on the enzyme affected and the site of excess porphyrin accumulation. Variegate
porphyria is classified as an acute, hepatic porphyria, and is caused by mutations in
protoporphyrinogen oxidase (ppox). The PPOX enzyme catalyzes the penultimate step of heme
biosynthesis, the oxidation of protoporphyrinogen to protoporphyrin in the mitochondria.
Clinical symptoms of variegate porphyria can include photocutaneous lesions and
neurovisceral dysfunction, including abdominal pain, peripheral neuropathy, and mental
disturbances (reviewed in [4]). Treatment of acute attacks primarily involves intravenous
hematin administration [2] to inhibit flux through the heme biosynthetic pathway and the
associated generation of porphyrins. If untreated, acute attacks can result in long-term or
permanent neurological and hepatic damage, or in some cases, can be fatal. While current
therapies are effective at treating acute attacks, preventative therapies are needed.
The zebrafish hematopoietic process is conserved throughout vertebrate evolution, as many
mouse and human homologues of blood-specific genes have been cloned in zebrafish,
including scl, lmo-2, gata-1, and the gene encoding the heme synthetic enzyme
coproporphyrinogen oxidase (CPO) [5], [6], [7], [8]. Several zebrafish models for
hematopoietic disease have been established, including dracula and yquem, which harbor
mutations in the genes encoding the heme biosynthetic enzymes, ferrochelatase and
uroporphyrinogen decarboxylase (UROD), respectively [9], [10]. The dracula and yquem
mutants display photosensitive porphyria, with characteristics representative of the
corresponding human disease syndromes.
We have characterized the zebrafish porphyric mutant, mno, and have cloned the responsible
gene, ppox. Initially, at the onset of circulation, mno displayed normal numbers of red blood
cells, but these cells were deficient in hemoglobin. By approximately 36 hpf, there was a visible
decrease in circulating erythrocytes, and fluorescence was observed when viewed under
epiflourescent light. The mno mutant zebrafish could survive to approximately 25 dpf. We
further demonstrated that human ppox could partially rescue the hypochromia in homozygous
mutants, illustrating evolutionary conservation of function. The zebrafish mno mutant will be
very useful for further elucidating the pathophysiology of variegate porphyria and identifying
chemical modifiers of this disease.
Materials and Methods
Zebrafish strains and maintenance
Zebrafish were maintained [11] and staged [12] as described previously. mnohq098 and
mnoia048 were identified in the Tübingen 2000 genetic screen, and maintained on the Tü strain.
For genetic mapping analyses, outcrosses to the wild-type WIK strain were performed.
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o-dianisidine staining and in-situ hybridization
Detection of hemoglobin by o-dianisidine was performed as described [13]. Whole-mount in-
situ hybridization with digoxigenin-labeled RNA probes was performed as described [6].
Meiotic mapping
Homozygous mutant mno embryos were collected from pairwise matings of mno heterozygotes
on the Tu/WIK background. Embryos were scored under a dissection microscope at
approximately 48 hours post fertilization (hpf) for anemia. Genomic DNA extraction from
individual embryos and bulk segregant analysis were performed as described [14] using
primers designed to SSLP markers obtained from the Massachusetts General Hospital
Zebrafish Server website (http://zebrafish.mgh.harvard.edu) and synthesized by Invitrogen.
Isolation of ppox cDNA from wild-type and mutant zebrafish
Total RNA was isolated from pools of 20 embryos at 72 hpf using the RNneasy lysis and
purification procedure (Qiagen). To obtain cDNA, reverse transcription was performed using
Superscript II reverse transcriptase (Invitrogen) in a 20 µl reaction. The reaction was then
diluted to 100 µl, and 10 ul of the dilution was used as template for each PCR reaction. The
full-length ppox cDNA was amplified from both wild type and mutant cDNA using primer
PPOX.F (5’-GCGCTGTCCAAATTACATTATTATA-3’) and PPOX.R (5’-
GCTTCAATCCCAAATAAACAGATGC-3’) with the following PCR conditions: 1 cycle of
94°C for 1 min; 39 cycles of 94°C for 1 min, 63°C for 1 min, 72°C for 1 min 30 sec; and 1
cycle of 72°C for 10 min. The RT-PCR products were subcloned into the pCRII vector Plasmid
DNA was purified using the Qiagen miniprep kit. Twelve independent clones of wild-type and
10 independent clones of mutant cDNA were sequenced.
Allele specific oligonucleotide (ASO) hybridization
Individual embryos from a heterozygous cross of mnohq098 were sorted at 72 hpf according to
anemic phenotype and stored in methanol at −20°C. Genomic DNA from the sorted embryos
and their PCR amplification were carried out essentially as described [15]. PCR amplifications
using genomic DNA as template with the two sets of primers spanning the two respective
mutations are as listed: (a) the nonsense mutation (L417X) [F1: 5'-
TAAAAACAATCCCTGTAACTCCCAG –3’ ; R1: 5'-
TAAAAACAATCCCTGTAACTCCCAG –3’ ] and (b) the missense mutation (N420S) [F2:
5'- TTATCATCACAGAGGCCATTTATGT -3'; R2: 5'-
CTTTAACCACCCACAATTGAAATG -3']. The PCR products were dotted onto nylon
membrane using a Schleicher & Schuell manifold and probed with ASO’s for the two
respective mutations in 3M tetramethyl ammonium chloride (Sigma) as described [16]. The
ASO’s for the nonsense mutation (L417X) are 5’-ACCTTTAGTAAAGCAACGC-3’ and 5’-
ACCTTTAGTTAAGCAACGC-3’, respectively for normal and mutant sequences. The ASO’s
for the missense mutation (N420S) are 5’-TTCTACAGAACTGCATTCC-3’ and 5’-
TTCTACAGAGCTGCATTCC-3’, respectively for normal and mutant sequences.
Morpholino injections
The zebrafish ppox intronic sequence was determined by comparison of zebrafish ppox cDNA
sequence, human genomic ppox sequence, and the Sanger Center zebrafish genome sequence
database (http://www.sanger.ac.uk/Projects/D_rerio/). Anti-sense morpholino oligos (Gene
Tools, Corvalis, Oregon) were designed to target either the ATG start site, or the exon 1/intron
boundary sequence (E/I), as follows: PPOX E/I MO (5’ – GCT AGT TCT CAC CTC AGA
GCC CAG C –3’); PPOX ATG MO (5’ – GCT ACA ACC TTC TGC ATT CAG CTC C –
3’). Morpholinos were resuspended in Danieau’s solution (58 mM NaCl, 0.7 mM KCl, 0.4 mM
MgSO4, 0.6 mM Ca(NO3)2, 5.0 mM Hepes, pH7.6). Wild type or heterozygous mutant
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pairwise matings were performed, and the resulting embryos were microinjected between the
1–4 cell stage with 1 nl of morpholino at a final concentration of 0.5 mM. Phenol Red was co-
injected as a tracer.
RNA microinjection
Full length human ppox cDNA was obtained from Open Biosystems (GenBank accession
#BC002357; vector pOTB7). The full length ppox cDNA was subcloned into pCS2+ using
EcoRI and XhoI. The resulting clone was linearized with XhoI, and full length mRNA was
transcribed from the SP6 promoter using mMessage mMachine according to manufacturer’s
protocol (Ambion). For rescue experiments, 200 pg or 500 pg of RNA was injected into
embryos from pairwise matings of heterozygous mno mutants.
Microarray analysis
Pools of 100 mnohq098−/− and 100 non-sibling wild type embryos were collected at 36 hpf.
RNA extraction, target preparation, hybridization, and signal detection were performed as
described previously [17].
Results
The zebrafish mutant, mno was identified in a forward genetic, ethylnitrosourea (ENU)
mutagenesis screen for embryonic hematopoietic defects. The mno mutant was first identified
as hypochromic anemic. At 48 hpf, circulating erythrocytes were visualized under a light
microscope in mnohq098−/− and wild type sibling embryos. There were fewer cells present in
mnohq098−/− embryos than in wild type siblings (data not shown) and the cells in
mnohq098−/− embryos lacked the red color indicative of hemoglobinized erythrocytes present
in wild type animals (Figure 1A). This phenotype is characteristic of hypochromic anemia in
zebrafish [18], [19], [20], [21]. When further observed under epiflourescent illumination using
a rhodamine filter, mnohq098−/− embryos exhibited fluorescence in the yolk sac (Figure 1B)
and in the tail vessels (Figure 1C), indicative of a porphyric phenotype [9], [10]. The mutation
displayed a recessive inheritance pattern, with 25% of embryos from single pairwise matings
of heterozygous (mnohq098+/−) zebrafish displaying the mutant phenotype.
A second allele, mnoia048, was also recovered in the ENU mutagenesis screen. The phenotype
of mnoia048−/− embryos is variable, as all homozygous embryos display yolk sac fluorescence,
but unlike mnohq098−/−, some embryos appear to have hemoglobinized erythrocytes pooling
under the yolk sac at 48 hpf under a light microscope (Figure 1D, E). In addition,
mnoia048−/− has yolk sac necrosis as early as 48 hpf, which is not observed in mnohq098−/−
homozygous mutants. The allelic relationship was confirmed by complementation analysis
with mnohq098 (data not shown).
Utilizing genetic linkage analysis, the region harboring the mno mutation was localized to an
approximate 3 cM interval (Figure 1F). Based on local synteny to human chromosome 21,
protoporphyrinogen oxidase (ppox), the gene encoding the penultimate enzyme in the heme
biosynthetic pathway, was identified as a potential candidate for the mno mutation. From
available partial genomic and cDNA sequences, primers were designed to amplify the entire
zfppox coding region from wild type and mnohq098−/− alleles. Subsequent sequencing revealed
two single base pair changes in 10 independent pools of mnohq098−/− embryos, T->A at position
1250 and A->G at position 1259. The first mutation, 1250T->A, results in a substitution of a
stop codon for leucine at amino acid residue 417 [L417X]. The second mutation results in a
substitution of serine for glutamine [N420S], but is presumably non-translated. The identified
mutations are shown in Figure 2A.
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The two mutations identified in mnohq098 were confirmed to segregate in a tightly linked
Mendelian manner by ASO hybridization (Fig. 2B). Genomic DNA’s from individual embryos
sorted based on anemic phenotype were amplified by PCR with flanking primers. The
amplicons were immobilized onto nylon membranes and hybridized with either normal or
mutant sequence ASO’s. Oligos corresponding to the 1250T->A and 1259A->G mutations
hybridized exclusively to the amplicons from mutant (lanes 5–8) and heterozygous embryos
(lanes 1 and 4); oligos corresponding to the normal sequences hybridized exclusively to
amplicons from wild type (lanes 2–3) and heterozygous embryos (lanes 1 and 4). The analysis
of an additional 48 sorted anemic mnohq098−/− embryos showed complete linkage of the two
mutant alleles, while 84 sorted, normal embryos were either wild type (n=32) or heterozygous
(n=52) genotype (data not shown).
Alignment of the predicted amino acid sequence for zebrafish PPOX with human and mouse
proteins reveals a 52% and 50% sequence conservation, respectively (Figure 2C). This
sequence is identical to a previous report by [8], except for one amino acid at position 105,
which is a leu in our sequence and a pro in the sequence reported by Hanaoka, et al. The
corresponding position in mouse and human PPOX is a leu. In human patients, disease
associated mutations in the ppox gene span the entire protein coding region [22], [23], as
indicated by the green and blue arrows in Figure 2C. The region of the protein downstream of
the L417X mutation in mno (indicated by black arrowhead) contains two conserved residues
known to bind the enzymatic cofactor FAD in tobacco protoporphyrinogen oxidase [24], as
indicated in Figure 2C.
To confirm that ppox is the affected gene in mno, we reproduced the mutant phenotype using
a morpholino knock-down technique (Figure 3). Wild type embryos were injected at the 1–4
cell stage of development with antisense morpholinos designed to decrease translation or post-
transcriptional splicing of ppox. Both the number of circulating erythrocytes and fluorescence
were evaluated at 48 hpf. In the presence of the morpholino, circulating erythrocytes were not
visible (data not shown). Yolk sac fluorescence was observed in 100% (n=88) of injected
animals (Figure 3B), in contrast to uninjected wild type embryos (n=104) (Figure 3D). In
addition, pericardial edema was observed in morpholino injected animals (Figure 3A, arrows).
To obtain further evidence that the montalcino mutation was due to a defect in ppox, embryos
from pairwise matings of mnohq09+−/− zebrafish were injected at the 1–4 cell stage with an
expression construct for human ppox. Injected embryos were stained at 36 hpf with o-
dianisidine, and genomic DNA was extracted for genotyping. Uninjected siblings served as
controls. Of the wild type embryos injected with human ppox RNA, normal levels of o-
dianisidine staining were observed (Figure 3E). Of the injected homozygous mutant embryos,
all 10 embryos displayed partial rescue of hemoglobinized erythrocytes, as indicated by o-
dianisidine staining (Figure 3G–H). Consistent with partial rescue of anemia, porphyria was
still observed in the humppox injected mutants (data not shown), suggesting that the
endogenous mutant ppox is still causing a partial block of heme synthesis and an accumulation
of porphyrin.
Expression of zebrafish ppox occurs as early as 22 hpf in the intermediate cell mass (ICM),
similar to the expression of other hematopoietic genes, including gata1, alas2, and β-
spectrin [5], [25], [26]. In mno mutants, ppox expression in the ICM at 22 hpf is unaltered, as
assessed by RNA in situ hybridization (Figure 4A). Other early hematopoietic markers were
also unaffected, including scl and gata1 (data not shown). We further characterized the onset
of the hematopoietic defect by analyzing the temporal expression pattern of erythrocyte specific
embryonic βe3-globin [27]. At the onset of circulation, approximately 28 hpf, homozygous
mnohq098−/− embryos display relatively normal numbers of erythrocytes, as shown by in situ
hybridization for βe3-globin (Figure 4B). However, the cells appear deficient in hemoglobin,
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as evidenced by pallor of the circulating erythrocytes (data not shown), and the absence of O-
dianisidine staining on the ventral yolk sac (Figure 4C). By 48 hpf, mnohq098 embryos become
anemic, confirmed by the absence of expression of β-globin (Figure 4D). To assess viability
of the mutation, we attempted to raise mno homozygotes to adulthood. Only 3/886 survived
beyond 7 dpf, and these animals died by approximately 27 dpf. At 25 dpf the surviving mutants
appeared stunted, pale, and slightly necrotic (Figure 4E).
To identify genes that display altered regulation, microarray analysis was performed,
comparing the expression profiles of wild type and homozygous mnohq098 embryos at 36 hpf
(Table 1). At this time point, there are still circulating erythrocytes in the mutants, but these
cells are hypochromic. Many of the downregulated genes in mnohq098 were erythrocyte
specific, including alas2, several embryonic globins and the membrane structural proteins,
band 4.1 and band 3. These results are consistent with the onset of anemia and hypochromia.
The number of upregulated genes was much larger, and included a peripheral benzodiazepine
receptor and several cytochromes, including cyt 2b, cyt 5, and cyt P450, which utilize heme as
part of prosthetic groups. The peripheral-type benzodiazepine receptor has been shown to
interact in vitro with protoporphyrin IX, the product of the PPOX enzyme, though the in
vivo function of this interaction is unclear [28], [29], [30].
Discussion
Utilizing the genetic synteny between human and zebrafish, we have identified a mutation in
the ppox gene that is responsible for the phenotypic abnormalities of the mno mutant. In
humans, variegate porphyria is characterized by photosensitivity and neurovisceral
dysfunction. The disease is most prevalent in South Africa, where a single C->T transition
resulting in an R59W substitution is responsible for the majority of clinical cases [31].
Subsequently, numerous mutations spanning the entire ppox gene have been identified in
patients with variegate porphyria [22], [23]. The mnohq098 mutation results in a stop codon in
the C-terminal region of the protein, eliminating a region that shares approximately 73%
conservation with human PPOX, and contains predicted FAD-binding domains [24].
The majority of human patients with variegate porphyria harbor heteroallelic mutations, and
we are aware of only one report of two patients harboring homoallelic mutations [32]. The
homoallelic mutations were missense mutations (D349A or A433P) located in the C-terminal
region of PPOX, flanking the mnohq098 mutation. Interestingly, unlike in humans,
mnohq098+/− heterozygous embryos grow to adulthood with no detectable symptoms of anemia
nor porphyria at anytime during development. The mnohq098−/− homozygous mutant embryos
display autoflourescence and necrosis, but also have anemia. No symptoms of anemia in human
variegate porphyria patients have been reported, even in the two patients with the homoallelic
mutations [22], [23], [32]. The reasons for these differences are unclear. One possible
explanation may be the optical clarity of the developing zebrafish embryo. In zebrafish, the
circulating RBCs are exposed to light from the earliest time in development, unlike in humans.
This may cause the RBCs to lyse, leading to anemia and ultimate death of the homozygous
embryos. The life span of the mnohq098−/− embryos is consistent with several other anemic
zebrafish mutants, including two alleles of the chianti mutant, ciahp327 and ciahs019 [21]. Other
anemic zebrafish mutants are able to survive to adulthood, for example sauternesty121 [25],
whereas the porphyric zebrafish mutant yquem is embryonic lethal [10]. It is not clear if the
ultimate cause of death in the mnohq098 mutant zebrafish embryos is due to the anemia and/or
a toxic accumulation of porphyrins.
Partial rescue of the mnohq098−/− phenotype by overexpression of human ppox demonstrates
the functional conservation of the enzyme across species. However, despite the partial rescue
of hemoglobinized erythrocytes, the autoflourescent phenotype was still observed. Given that
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in human patients, the disease has an autosomal dominant inheritance pattern, the endogenous
homozygous mutant PPOX in the partially rescued zebrafish may still be diverting flux of the
heme biosynthetic pathway, resulting in an accumulation of toxic porphyrins.
Using microarray analysis, many genes were identified as aberrantly regulated in the mno
mutant. Most of the downregulated genes were erythrocyte specific, such as several embryonic
beta globins and band3 [33], correlating with the decrease in circulating red blood cells
observed at 36 hpf. A much larger number of genes were shown to be upregulated, including
several cytochromes and a benzodiazepine receptor. The cytochromes utilize heme in the
prosthetic groups, and the upregulation may reflect a positive feedback loop when heme is
limiting. The peripheral-type benzodiazepine receptor (PBR) is associated with numerous
biological functions, including porphyrin transport and neurological and neuropsychiatric
diseases (reviewed in [34]). PBR has been shown to bind protoporphyrin IX, the product of
PPOX, with nanomolar affinity in vitro. However, the endogenous function of this interaction
has not been defined (reviewed in [35]). The underlying basis of the neurological symptoms
of porphyria is not well understood. Future investigations into the relationship between PBR
and porphyrins may lead to treatments for the neurological aspects of variegate porphyria, as
well as other classes of porphyria.
The list of upregulated genes observed in mno mutants also included apolipoproteins,
corticosteroids, and very long chain acyl coA synthetase, genes important for steroid
biosynthesis and fatty acid metabolism. A report [36] has revealed a previously unknown link
between the liver specific 5-aminolevulinate synthase 1 (ALAS1) and peroxisome proliferator-
activated receptor γ coactivator 1α (PGC-1α), a transcriptional coactivator whose expression
is upregulated during fasting. Unlike ALAS2, ALAS1 is ubiquitously expressed, and its
primary role in the liver is the generation of heme for cytochrome biosynthesis. Several dietary
factors, including fasting, are known to precipitate acute porphyric attacks by an unknown
mechanism. Handschin and colleagues demonstrate that PGC-1α mediates an increase in
ALAS1 expression during fasting, increasing the level of heme precursors, which precipitates
acute porphyric attacks in patients with defects in heme biosynthetic enzymes. Here, steroid
and fatty acid genes upregulated in the microarray analysis represent another link between the
nutritional status and porphyria. Future investigation will elucidate the significance of this
relationship.
Several other zebrafish mutants display a porphyric phenotype, including yquem [10],
dracula [9], and freixenet [13]. In yquem and dracula mutants, the affected heme biosynthetic
enzymes are ferrochetalase and UROD, respectively. More recently, a zebrafish model for
coproporphyria (HCP) was created by injecting a morpholino targeting coproporphyrinogen
oxidase (CPO) [8]. In addition, the previously identified zebrafish mutants, shiraz [37] and
sauternes [25] both have hypochromic anemia, but are not porphyric. The shiraz mutation is
within the glutaredoxin 5 gene, which has a downstream effect on ALAS2 activity, whereas
the sauternes mutation is in the alas2 gene itself. Thus, as in humans, ALAS2 mutations do
not result in porphyria. The heme biosynthetic pathway is highly conserved between zebrafish
and humans, and the mno mutant therefore represents a powerful model to dissect the
underlying mechanisms of variegate porphyria and a means to identify potential new therapies.
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Figure 1. Blood phenotype and genetic linkage analysis of montalcino
Homozygous mutant embryos (mnohq098−/−) display hypochromic anemia at 48 hpf under
bright light. A) Arrows indicate the cardiac region, where red tint of red blood cells (RBC) can
be seen in the wild type animals but not homozygous mutant siblings. B) In contrast to wild
type siblings (top), mnohq098−/− embryos (bottom) display autoflourescence when analyzed
under a flourescent light microscope with a Texas Red filter. C) Autoflourescence can be
visualized in the posterior tail vessels of mnohq098−/− embryos. D) At 48 hpf, homozygous
mutant embryos (mnoia048−/−) under display pooling of RBCs under the yolk sac (arrows). E)
When viewed under a fluorescent light microscope with a Texas Red filter, these same
mnoia048−/− embryos display autoflourescence in the yolk sacs, in contrast to wild type siblings
(no arrows). F) Genetic linkage analysis localized the mutation to LG16. Syntenic relationship
between human chromosome 1 and zebrafish LG 16 identified the ppox gene as a candidate
for the genetic lesion.
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Figure 2. Mutation in ppox of mnohq098−/− results in premature stop codon
A) RT-PCR was performed on pools of homozygous wt or homozygous mutant embryos. The
entire ppox cDNA was sequenced, revealing single base pair changes as indicated. The first T
->A mutation at position 1250 results in premature translational termination, and the second,
presumably non-translated, A->G mutation, results in serine for glutamine substitution. B)
Genomic DNA from individual embryos, sorted based on anemic phenotype, was amplified
using primers flanking the mutated region identified from the cDNA sequencing. Allele
specific oligo hybridization confirmed the presence of both single base pair mutations in mutant
embryos, as shown. An additional 48 homozygous mutants, 52 heterozygous wild type, and
32 homozygous wild type embryos further confirmed linkage (not shown). C) Alignment of
zebrafish ppox with human and mouse. (black arrow - position of stop generated in
mnohq098−/− ; blue arrow - south African mutation, R59W; green arrow - mutations identified
in human patients; red arrow - FAD binding residues, human).
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Figure 3. Morpholino knockdown and RNA rescue confirm ppox as the gene responsible for defects
in montalcino
Wild type embryos were injected with ppox MO and assayed for fluorescence. A,B) Live
images of injected wild type embryos at 48 hpf under bright light (A) or bright light with a
Texas Red Filter (B). Injected embryos display pericardial edemia (arrows in (A)) and
fluorescence in RBC and yolk sac (B). C,D) Control, uninjected wild type embryos at 48 hpf.
E–H) Embryos from pairwise mating of mnohq098+/− were injected with full length, human
ppox RNA and stained with o-dianisidine at 48 hpf, to detect hemoglobinized RBC. E) Wild
type uninjected embryo. F) uninjected mnohq098−/− , G, H) Injected mnohq098−/−.
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Figure 4. Hematopoietic phenotype of montalcino
A) RNA in situ hybridizations were performed on embryos from pairwise matings of
mnohq098+/−. A) zfppox was expressed to wild type levels in the ICM of 100% of animals. B)
At 28 hpf, βe3-globin was expressed to wild type levels in circulating RBC of 100% of animals,
indicating normal numbers of circulating erythrocytes in mnohq098−/− embryos. C) o-
dianisidine staining for hemoglobinized erythrocytes at 28 hpf revealed early onset
hypochromia in 25% of animals. D) at 48 hpf, loss of βe3-globin expression in 25% of animals
revealed anemia. E) The phenotype at 25 dpf of the very few animals that survive past day 7
is shown. Animals are pale, short, and have regions of necrosis. None were able to survive past
day 28.
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Table 1
Microarray analysis of montalcino embryos at 36 hpf
UniGene Annotation Probe Set ID Mean Fold Change (log
based)
Cleavage and polyadenylation specificity factor, 73 kDa subunit Dr.24764.1.S1_at 2.59
Forkhead box protein L1 (Forkhead-related protein FKHL11) (Transcription factor FKH Dr.15390.1.A1_at 2.47
embryonic globin beta e2 DrAffx.2.15.S1_at 2.42
zona pellucida glycoprotein 4 preproprotein Dr.19916.2.A1_s_at 2.23
alas2: aminolevulinate, delta-, synthetase 2 Dr.8180.1.S1_at 1.58
Danio rerio erythroid band 3 anion exchanger 1 (ae1) Dr.20971.1.S2_at 1.47
D-amino acid oxidase Dr.3663.1.A1_at 1.46
epb41: erythrocyte membrane protein band 4.1 (elliptocytosis 1, RH-linked) Dr.3027.1.S1_at 1.41
Dr.6952.1.A1_at 1.30
MAP kinase-interacting serinethreonine kinase 1; MAP kinase interacting kinase 1 Dr.25422.1.S1_s_at 1.10
hbae3: hemoglobin alpha embryonic-3 Dr.1450.1.S1_s_at 1.10
JC2436 5-nucleotidase Dr.3959.1.A1_at 0.99
pklr: pyruvate kinase, liver and RBC Dr.1699.1.A1_at 0.95
hbae3: hemoglobin alpha embryonic-3 Dr.1450.1.S1_at 0.90
Embryonic Globin gene Be1 DrAffx.1.85.S1_s_at 0.66
rbp4: retinol binding protein 4, plasma Dr.5479.1.S1_at −0.55
hspa9b: heat shock protein 9B Dr.4503.1.S2_at −0.64
keratin 21, type I, cytoskeletal - rat Dr.12425.2.S1_a_at −0.66
hspd1: heat shock 60kD protein 1 (chaperonin) Dr.7108.1.S1_at −0.67
NADH dehydrogenase Dr.434.1.S1_at −0.67
DnaJ (Hsp40) homolog, subfamily A, member 2 Dr.25140.2.S1_at −0.73
Dr.19902.3.S1_at −0.74
Keratin, type I cytoskeletal 14 Dr.12425.5.S1_a_at −0.77
CGI-107 protein [Homo sapiens Dr.24930.1.S1_at −0.78
succinate dehydrogenase complex, subunit A, flavoprotein (Fp) Dr.11239.1.S1_at −0.78
ucp2: uncoupling protein 2 Dr.21244.1.S1_at −0.79
Dr.2518.1.A1_at −0.80
sod1: superoxide dismutase 1, soluble Dr.20938.1.S1_at −0.81
RDH1_HUMAN 11-cis retinol dehydrogenase Dr.13301.1.S1_at −0.83
Dr.11029.1.A1_at −0.86
hspa9b: heat shock protein 9B Dr.4503.1.S1_at −0.87
Cystathionine gamma-lyase Dr.3560.1.A1_at −0.93
mat2a: methionine adenosyltransferase II, alpha Dr.2850.1.S1_at −0.96
probable flavoprotein-ubiquinone oxidoreductase Dr.24219.5.S1_at −0.96
anti-sigma cross-reacting protein homolog I alpha precursor - human Dr.6709.1.S1_at −0.98
Dr.467.1.A1_at −0.99
Kelch-like ECH-associated protein 1 (Cytosolic inhibitor of Nrf2) Dr.6806.1.S1_at −1.03
Apolipoprotein D precursor (Apo-D) (ApoD). Dr.15815.1.A1_at −1.03
HIV gp120-binding C-type lectin - human Dr.14963.1.A1_at −1.04
Cytochrome c-type heme lyase Dr.4423.1.S1_at −1.06
similar to photorepair Dr.23983.1.A1_at −1.07
helicase, lymphoid specific; proliferation-associated SNF2-like [Mus musculus] Dr.26546.1.A1_at −1.10
Dr.19.1.A1_at −1.10
Heat shock protein 67B2 Dr.18607.1.S1_at −1.11
COX15 homolog, isoform 1 precursor; cytochrome c oxidase subunit 15; cytochrome c Dr.11635.1.A1_at −1.11
gclc: glutamate-cysteine ligase, catalytic subunit Dr.7271.1.S1_at −1.14
CYR61 protein precursor (Cysteine-rich, angiogenic inducer, 61)(Insulin-like growth fac Dr.15501.1.S1_at −1.14
hig1: hypoxia induced gene 1 Dr.13321.1.S2_at −1.15
Tubulin beta-2 chain Dr.23801.1.A1_at −1.17
Dr.14702.1.A1_at −1.19
SURF-1 protein - mouse Dr.14568.1.S1_at −1.19
benzodiazepine receptor, peripheral-type - human Dr.20778.1.S1_at −1.20
probable thioredoxin peroxidase Dr.10624.1.S1_at −1.20
hypothetical protein FLJ20487 [Homo sapiens]. Dr.8010.1.S1_at −1.22
Dr.3266.1.A1_at −1.23
Dr.22988.1.A1_at −1.23
hypothetical protein PP591 Dr.13364.1.S1_at −1.24
core1 UDP-galactose:N-acetylgalactosamine-alpha-R beta 1,3-galac Dr.6223.1.A1_at −1.25
Corticosteroid 11-beta-dehydrogenase, isozyme 1 Dr.16029.1.S1_at −1.27
Dr.1870.1.A1_at −1.27
Retinoic acid-binding protein II, cellular Dr.25576.1.A1_at −1.29
RAD51-like 1 isoform 1 Dr.17199.1.S1_at −1.29
titin, cardiac muscle Dr.11748.1.A1_at −1.29
alpha-A crystallin Dr.17476.1.A1_at −1.30
retinol dehydrogenase 14 (all-trans and 9-cis); PAN2 protein Dr.21921.1.A1_at −1.32
hig1: hypoxia induced gene 1 Dr.13321.1.S1_at −1.33
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UniGene Annotation Probe Set ID Mean Fold Change (log
based)
epoxide hydrolase Dr.17186.1.S1_at −1.33
probable thioredoxin peroxidase Dr.10624.2.S1_at −1.39
dio1: deiodinase, iodothyronine, type I Dr.24960.1.S1_at −1.41
Selenoprotein X 1 Dr.13967.1.A1_at −1.43
Dr.21377.1.A1_at −1.43
Dr.3429.1.A1_at −1.46
helicase, lymphoid specific; proliferation-association SNF2-like [Mus musculus] Dr.4544.1.S1_at −1.46
IRG1_MOUSE IMMUNE-RESPONSIVE PROTEIN 1 Dr.10914.1.A1_at −1.47
Dr.5517.1.A1_at −1.50
probable thioredoxin peroxidase Dr.10624.2.S1_a_at −1.57
Dr.5517.2.S1_at −1.63
Very-long-chain acyl-CoA synthetase Dr.12740.1.A1_at −1.63
Dr.26514.1.A1_at −1.66
tef: thyrotroph embryonic factor Dr.578.1.A1_at −1.73
NADPH-cytochrome P450 reductase Dr.13867.1.A1_at −1.80
cry2b: cryptochrome 2b Dr.10330.1.S1_at −1.81
tef: thyrotroph embryonic factor Dr.578.2.S1_a_at −1.83
lipocalin-type prostaglandin D synthase-like protein Dr.1192.1.S1_at −1.85
Dr.18661.1.A1_at −1.86
55 KDA ERYTHROCYTE MEMBRANE PROTEIN Dr.17659.1.S1_at −1.90
Dr.6401.1.S1_at −2.00
xeroderma pigmentosum group C repair complementing protein p12 Dr.4069.1.A1_at −2.16
Proline oxidase, mitochondrial precursor Dr.12460.1.A1_at −2.23
cry5: cryptochrome 5 Dr.10332.1.S1_at −2.25
abhydrolase domain containing 4 [Homo sapiens]. Dr.14922.1.A1_at −2.29
xeroderma pigmentosum group C repair complementing protein p125 Dr.19728.1.A1_at −2.30
lipocalin-type prostaglandin D synthase-like protein Dr.1192.1.S1_a_at −2.32
period 2 circadian clock protein DrAffx.2.2.S1_at −2.33





mpx: myeloid-specific peroxidase Dr.9478.2.S1_at −2.47
per2: period homolog 2 (Drosophila) Dr.6754.1.A1_at −2.48
92 kDa type IV collagenase precursor (MMP-9) Dr.967.1.S1_at −2.51
Dr.12694.1.A1_at −2.52
ribonucleoside-diphosphate reductase Dr.2906.1.S1_at −2.53
Dr.23441.1.S1_at −2.68
weakly similar to Estradiol 17 beta-dehydrogenase 4 Dr.8914.1.S1_at −2.71
mpx: myeloid-specific peroxidase Dr.9478.1.S1_at −2.77
heme binding protein 2 Dr.18410.1.S1_at −2.80
zcry-dash: cryptochrome dash Dr.18310.2.A1_at −2.86
Dr.18657.2.A1_at −2.88
Dr.9849.1.A1_at −2.90
zcry-dash: cryptochrome dash Dr.18310.1.S1_at −2.97
vg1: vitellogenin 1 Dr.25009.6.A1_a_at −2.99
Dr.21447.1.A1_at −3.02
Heat shock cognate 71 kDa protein Dr.25639.1.A1_at −3.02
Dr.23741.1.S1_at −3.09
ATP-binding cassette, sub-family G, member 2; breast cancer resistance protein; mito Dr.22153.1.A1_at −3.17
Dr.7799.1.A1_at −3.22
nuclear factor, interleukin 3, regulated [Rattus norvegicus] Dr.17447.1.A1_at −3.24
lipocalin-type prostaglandin D synthase-like protein, Dr.1192.2.S1_at −3.67
apolipoprotein D - mouse Dr.16052.1.S1_at −3.69
Complement component C7 precursor Dr.96.1.A1_at −3.70
cartilage acidic protein 1 Dr.6210.1.S1_at −3.82
fos: v-fos FBJ murine osteosarcoma viral oncogene homolog Dr.12986.2.S1_at −3.93
Dr.17061.1.A1_at −4.88
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